TUCSON, Ariz., Dec. 8, 2020 /PRNewswire/ --Procyon Technologies LLC today announced that it has entered into an exclusive research collaboration and license agreement with Novo Nordisk A/S to develop an implantable cell encapsulation device to be used in Novo Nordisk's development of a novel therapy for Type 1 diabetes.
Older, male patients with more severe underlying conditions and a greater risk of death tended to be more accepting of new approaches such as stem cell research A new review of research bringing together patient, carer and public views of cell and gene therapies has highlighted a need for appropriate education to better inform people including how clinical trials work and the risks and benefits of various treatments.
Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Patients who are profoundly immunosuppressed after extensive cancer treatment, and who fall ill with COVID-19, can shed viable SARS-CoV-2 virus for at least 2 months after symptom onset, and may need extended periods of isolation. Live-virus shedding was detected in 18 patients who had undergone hematopoietic stem cell transplants or chimeric antigen receptor (CAR) T-cell therapy and in 2 patients with lymphoma.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced clinical data from its ongoing multicenter Phase 1 clinical trial of JSP191, a first-in-class anti-CD117 monoclonal antibody, in patients with severe combined immune deficiency (SCID). The trial is evaluating JSP191 as a conditioning agent to enable stem cell transplantation in patients with SCID who are either transplant-naive or who received a prior stem cell transplant with a poor outcome. Data from the first transplant-nave SCID patient in the Phase 1 trial, a 6-month-old infant, showed that a single dose of JSP191 administered prior to stem cell transplant was effective in establishing sustained donor chimerism followed by development of B, T and NK immune cells
HealthA new stem cell treatment could restore eyesight in some people Friday, 4th December 2020, 3:18 pm Researchers discovered that the cells of damaged retinas could be repaired by injecting genetically modified stem cells into the eye. Sign up to our public interest bulletins - get the latest news on the Coronavirus Sign up to our public interest bulletins - get the latest news on the Coronavirus The news comes as comedian Al Murray pushed for stem cell donors to come forward, ahead of a charity gig for blood cancer organisation DKMS.
Reactive oxygen molecules, also known as "free radicals", are generally considered harmful. However as it now turns out, they control cellular processes, which are important for the brain's ability to adapt - at least in mice. Researchers from the German Center for Neurodegenerative Diseases (DZNE) and the Center for Regenerative Therapies Dresden (CRTD) at TU Dresden published the findings in the journal Cell Stem Cell
Newswise LOS ANGELES (Dec. 4, 2020) -- Cedars-Sinai has launched a center to manufacture the next generation of stem cell and gene therapies that will enable biomedical researchers, government medical programs, commercial entities and others to develop new biologic drugs and propel novel disease discoveries. Biologic drugs are produced from living organisms or contain components of living organisms, such as cells, proteins or genes.
Dublin, Dec. 03, 2020 (GLOBE NEWSWIRE) -- The "Stem Cell Therapy Global Market Insights 2020, Analysis and Forecast to 2025, by Manufacturers, Regions, Technology, Product Type" report has been added to ResearchAndMarkets.com's offering. This report describes the global market size of Stem Cell Therapy from 2015 to 2019 and its CAGR from 2015 to 2019, and also forecasts its market size to the end of 2025 and its CAGR from 2020 to 2025
For Evie Junior, living with sickle cell disease has been like running a marathon. But its a marathon where as you keep going, the trail gets rockier and then you lose your shoes, the 27-year-old said. It gets harder as you get older.
UCLA has received a $7.3 million grant from the National Institutes of Health to build a state-of-the-art facility in which to produce gene and cell therapies aimed at treating a host of illnesses and conditions.
Recent Comments